MannKind signs sale-leaseback agreement for inhaled insulin manufacturing site
The transaction will generate $102.25 million to support the company's product pipeline and scaling up commercial activities for Afrezza
MannKind, which makes an ultra rapid-acting inhaled insulin product for diabetes in the US, has entered into a sale-leaseback transaction to unlock value tied up in its Danbury, Connecticut manufacturing facility .
The company's CEO Michael Castagna said the $102.25 million transaction will support the company's "growing product pipeline" and its "targeted scale-up of Afrezza commercial activities and clinical trials".
The real property sale includes 263,900 sq. ft of manufacturing space, where it produces Afrezza (insulin human) Inhalation Powder, the company’s first US Food and Drug Administration-approved product and the only inhaled ultra rapid-acting mealtime insulin in the US.
It is also where MannKind is preparing to manufacture Tyvaso DPI (inhaled treprostinil), which is is currently being reviewed by the FDA for its potential to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, under its collaboration with United Therapeutics.
The transaction does not, however, extend to MannKind’s research and development facility.
Upon closing of the agreement, the endocrine and orphan lung diseases specialist will enter into a 20-year lease agreement with the purchaser — an affiliate of Creative Manufacturing Properties — with multiple renewal options available.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.